- Home
- DH vs MREO Comparison
DH vs MREO Comparison
Compare DH & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DH
- MREO
- Stock Information
- Founded
- DH 2011
- MREO 2015
- Country
- DH United States
- MREO United Kingdom
- Employees
- DH N/A
- MREO N/A
- Industry
- DH Computer Software: Prepackaged Software
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- DH Technology
- MREO Health Care
- Exchange
- DH Nasdaq
- MREO Nasdaq
- Market Cap
- DH 283.1M
- MREO 288.0M
- IPO Year
- DH 2021
- MREO N/A
- Fundamental
- Price
- DH $2.62
- MREO $1.76
- Analyst Decision
- DH Hold
- MREO Strong Buy
- Analyst Count
- DH 6
- MREO 5
- Target Price
- DH $4.28
- MREO $7.40
- AVG Volume (30 Days)
- DH 263.1K
- MREO 1.5M
- Earning Date
- DH 11-06-2025
- MREO 11-10-2025
- Dividend Yield
- DH N/A
- MREO N/A
- EPS Growth
- DH N/A
- MREO N/A
- EPS
- DH N/A
- MREO N/A
- Revenue
- DH $242,275,000.00
- MREO $500,000.00
- Revenue This Year
- DH N/A
- MREO N/A
- Revenue Next Year
- DH $0.68
- MREO $72.16
- P/E Ratio
- DH N/A
- MREO N/A
- Revenue Growth
- DH N/A
- MREO N/A
- 52 Week Low
- DH $2.15
- MREO $1.47
- 52 Week High
- DH $5.68
- MREO $3.94
- Technical
- Relative Strength Index (RSI)
- DH 36.58
- MREO 41.49
- Support Level
- DH $2.51
- MREO $1.75
- Resistance Level
- DH $2.92
- MREO $1.90
- Average True Range (ATR)
- DH 0.16
- MREO 0.11
- MACD
- DH 0.01
- MREO -0.01
- Stochastic Oscillator
- DH 19.79
- MREO 39.29
About DH Definitive Healthcare Corp.
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).